Novel and replicated clinical and genetic risk factors for toxicity from high‐dose methotrexate in pediatric acute lymphoblastic leukemia
暂无分享,去创建一个
M. Scheurer | P. Lupo | K. Rabin | M. Bernhardt | K. Kamdar | M. Zobeck
[1] F. Wen,et al. Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning , 2021, International Journal of Hematology.
[2] M. Scheurer,et al. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene , 2021, Pediatric blood & cancer.
[3] M. Kay. Tidy Data and 'Geoms' for Bayesian Models [R package tidybayes version 2.3.1] , 2020 .
[4] M. Scheurer,et al. Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia , 2020, Leukemia & lymphoma.
[5] A. Gafter-Gvili,et al. Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies , 2020, Hematological oncology.
[6] R. Viney,et al. Financial toxicity of childhood cancer and changes to parents’ employment after treatment completion , 2020, Pediatric blood & cancer.
[7] A. Vinks,et al. MTXPK.org: A Clinical Decision Support Tool Evaluating High‐Dose Methotrexate Pharmacokinetics to Inform Post‐Infusion Care and Use of Glucarpidase , 2020, medRxiv.
[8] Matthew Kay. tidybayes: Tidy Data and Geoms for Bayesian Models , 2020 .
[9] A. Siryk,et al. Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia , 2019, Blood.
[10] S. Medellín-Garibay,et al. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia , 2019, Cancer Chemotherapy and Pharmacology.
[11] G. Michel,et al. The impact of childhood cancer on parents' socio‐economic situation—A systematic review , 2019, Psycho-oncology.
[12] S. Hilsenbeck,et al. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities , 2018, Cancer Chemotherapy and Pharmacology.
[13] Austin L. Brown,et al. Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients , 2018, Clinical Cancer Research.
[14] Tao-tao Liu,et al. Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia , 2018, Chemotherapy.
[15] Paul-Christian Bürkner,et al. brms: An R Package for Bayesian Multilevel Models Using Stan , 2017 .
[16] K. Schmiegelow,et al. Delayed elimination of high‐dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia , 2017, Pediatric blood & cancer.
[17] Aki Vehtari,et al. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC , 2015, Statistics and Computing.
[18] S. Cole,et al. Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study , 2017, BMC Medical Genetics.
[19] S. Devlin,et al. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia , 2016, Annals of Hematology.
[20] C. Pui,et al. Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.
[21] G. Phillips,et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[22] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[23] L. Almasy,et al. Genome-wide association analysis confirms and extends the association of SLC2A9 with serum uric acid levels to Mexican Americans , 2013, Front. Genet..
[24] M. Loh,et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. , 2013, Blood.
[25] G. Kovács,et al. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia , 2013, Anti-cancer drugs.
[26] E. Lopez-Lopez,et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia , 2013, Pharmacogenetics and genomics.
[27] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[28] Xiaomin Lu,et al. Plasma Methotrexate, Red Blood Cell Methotrexate, and Red Blood Cell Folate Values and Outcome in Children With Precursor B-acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group , 2012, Journal of pediatric hematology/oncology.
[29] G. Rosner,et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. , 2012, Genome research.
[30] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[31] Russ B Altman,et al. PharmGKB summary: methotrexate pathway. , 2011, Pharmacogenetics and genomics.
[32] Cedric E. Ginestet. ggplot2: Elegant Graphics for Data Analysis , 2011 .
[33] R. Altman,et al. SLC19A1 pharmacogenomics summary , 2010, Pharmacogenetics and genomics.
[34] I. Christensen,et al. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. , 2010, Blood.
[35] R. Mei,et al. A genomewide admixture mapping panel for Hispanic/Latino populations. , 2007, American journal of human genetics.
[36] E. Cook,et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. , 2007, Blood.
[37] Ching-Hon Pui,et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. , 2006, Blood.
[38] P. Adamson,et al. Understanding and managing methotrexate nephrotoxicity. , 2006, The oncologist.
[39] J. Lukas,et al. Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia , 2006, Clinical pharmacokinetics.
[40] J. Downing,et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. , 2005, The Journal of clinical investigation.
[41] K. Ness,et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. , 2003, JAMA.
[42] M. Kuwano,et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. , 2002, Cancer research.
[43] D. Murry,et al. Impact of nutrition on pharmacokinetics of anti‐neoplastic agents , 1998, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[44] J. Daly,et al. Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics , 1984, Cancer.
[45] V. Grossie,et al. Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat. , 1982, Cancer treatment reports.